Skip to main content
Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
Is multiple sclerosis a risk factor for infections?
The future of microbiome research in neuroinflammatory disorders.
The COVID-19 pandemic and the use of MS disease-modifying therapies.
Big pharma and social responsibility.
Ageing and multiple sclerosis.
"Is this new medicine going to help me walk again?"
Silent symptoms of multiple sclerosis.
The multiple sclerosis gut microbiota: A systematic review.
Grassroot efforts towards diversity in MS care and research: Win-win for patients and science.